Single Cell Technology adds to international porfolio of patents

4 June 2018

Single Cell Technology has expanded its international patent portfolio, India Patent No. 296142 titled "Method of screening single cells for the production of biologically active agent" was issued on Apr. 25, 2018. This patent brings the total number of issued international patents to 6 and total issued patents to 11. Patents are also held in Canada, South Korea, Europe, Australia, and Japan.

Dr. Chun-Nan Chen, Founder and CEO has been the driving force behind the impressive number of patents protecting SCT technology. "This patent covers SCT's core methodology in the broadest applications including but not limited to antibody discovery. The invention can be used for T cell receptor identification and beyond," he commented.

Recent News

New mechanism that predicts a competitive advantage to SARS-CoV-2 virus carrying the D614G spike mutation

Jun 15, 2020

A manuscript studying a prominent mutation in SARS-CoV-2 has been published on a preprint server by partners Single Cell Technology and Antibody Solutions.

Read More+

SCT to present candidate selection workflow at Antibody Engineering & Therapeutics

Jun 15, 2020

SCT to present a candidate selection workflow of AbTheneum output at Antibody Engineering & Therapeutics using BCMA, TIGIT, and TIM3 to demonstrate the year-long effort. The presentation will be given on Wednesday, December 11 at the Marriott Marquis in San Diego…

Read More+

ACROBiosystems brings high affinity anti-BCMA antibodies, attending Fifteenth Annual PEGS Boston 2019

Apr 8, 2019

ACROBiosystems, a leading manufacturer of recombinant proteins and critical reagents to the biopharma industry, today announced at the PEGS – Protein Engineering Summit the successful completion of isolation and characterization of a large panel of anti-human BCMA antibodies for the purpose of treating multiple myeloma cancer.

Read More+